Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer death in the United States. Paradoxically, CRC is a preventable cancer; long-dwelling pre-cancerous polyps can be detected during screening and excised. Screening has also been demonstrated to detect cancers at earlier stages, when survival rates are high and direct medical costs are low. However, CRC screening is still generally underutilized; current U.S. participation rates are below 50%. We are interested in the strengths and limitations of available screening tests, including their relative cost-effectiveness. Since health care resources are not infinite, cost-effective screening strategies need to be identified and promoted.